1 month Zacks Research Issues Optimistic Forecast for ALLO EarningsMarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Equities researchers at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research note issued on Tuesday, October 22nd. Zacks Re…
Earnings · Nasdaq 100 · Science
X